

1 Nasopharyngeal Angiotensin Converting Enzyme 2 (ACE2) Expression as a Risk-Factor 2 for SARS-CoV-2 Transmission in Concurrent Hospital Associated Outbreaks

3
4 Aidan M. Nikiforuk^{1,4}, Kevin S. Kuchinski^{1,2}, Katy Short³, Susan Roman³, Mike A. Irvine¹,
5 Natalie Prystajecky^{1,2}, Agatha N. Jassem^{1,2}, David M. Patrick^{1,4} and Inna Sekirov^{1,2}

6
7 ¹ British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada

8 ² Department of Pathology and Laboratory Medicine, University of British Columbia,
9 Vancouver, BC V6T 1Z4, Canada

10 ³ Fraser Health Authority, New Westminster, BC V3L 3C2, Canada

11 ⁴ School of Population and Public Health, University of British Columbia, Vancouver, BC V6T
12 1Z4, Canada

13 ⁵ Faculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada

14 15 16 **Abstract:**

17
18 *Background:* Widespread human-to-human transmission of the severe acute respiratory
19 syndrome coronavirus two (SARS-CoV-2) stems from a strong affinity for the cellular receptor
20 angiotensin converting enzyme two (ACE2). We investigate the relationship between a patient's
21 nasopharyngeal ACE2 transcription and secondary transmission within a series of concurrent
22 hospital associated SARS-CoV-2 outbreaks in British Columbia, Canada.

23
24 *Methods:* Epidemiological case data from the outbreak investigations was merged with public
25 health laboratory records and viral lineage calls, from whole genome sequencing, to reconstruct
26 the concurrent outbreaks using infection tracing transmission network analysis. ACE2
27 transcription and RNA viral load were measured by quantitative real-time polymerase chain
28 reaction. The transmission network was resolved to calculate the number of potential secondary
29 cases. Bivariate and multivariable analyses using Poisson and Negative Binomial regression
30 models was performed to estimate the association between ACE2 transcription the number of
31 SARS-CoV-2 secondary cases.

32
33 *Results:* The infection tracing transmission network provided $n = 76$ potential transmission
34 events across $n = 103$ cases. Bivariate comparisons found that on average ACE2 transcription did
35 not differ between patients and healthcare workers ($P = 0.86$). High ACE2 transcription was
36 observed in 98.6% of transmission events, either the primary or secondary case had above
37 average ACE2. Multivariable analysis found that the association between ACE2 transcription and
38 the number of secondary transmission events differs between patients and healthcare workers. In
39 health care workers Negative Binomial regression estimated that a one unit change in ACE2
40 transcription decreases the number of secondary cases ($B = -0.132$ (95%CI: -0.255 to -0.0181)
41 adjusting for RNA viral load. Conversely, in patients a one unit change in ACE2 transcription
42 increases the number of secondary cases ($B = 0.187$ (95% CI: 0.0101 to 0.370) adjusting for
43 RNA viral load. Sensitivity analysis found no significant relationship between ACE2 and
44 secondary transmission in health care workers and confirmed the positive association among
45 patients.

47 *Conclusion:* Our study suggests that *ACE2* transcription has a positive association with SARS-
48 CoV-2 secondary transmission in admitted inpatients, but not health care workers in concurrent
49 hospital associated outbreaks, and it should be further investigated as a risk-factor for viral
50 transmission.

51
52 **Keywords:** ACE2, SARS-CoV-2, Infection Tracing, Transmission Network, Outbreak
53 Investigation, Multivariable Analysis, Poisson Regression Model, Negative Binomial Regression
54

55 **Introduction:**

56 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes potentially
57 life threatening lower respiratory and systemic inflammatory disease defined as COVID-19[1–3].
58 SARS-CoV-2 has spread widely since late 2019 causing a global pandemic. Two previous public
59 health emergencies have provided the opportunity to study human-to-human transmission of
60 pathogenic coronaviruses. In 2003, the severe acute respiratory syndrome emerged infecting
61 eight-thousand four-hundred and twenty-two people [4]. In 2012 and 2015 the Middle East
62 respiratory syndrome coronavirus (MERS-CoV) caused epidemics in the Kingdom of Saudi
63 Arabia and South Korea with two-thousand five hundred and sixty-two laboratory confirmed
64 cases reported to the World Health Organization[5]. SARS- and MERS-CoV spread
65 predominately in health care settings and community spread was controlled by public health
66 interventions or self-limited[4,5]. The transmission pattern of SARS-CoV-2 contrasts that of the
67 other pathogenic coronaviruses (SARS-CoV and MERS-CoV). SARS-CoV-2 has predominately
68 spread within the community, the virus has evolved to become more infectious over time and
69 vaccination does not protect against re-infection or transmission of newer strains [6].
70 Transmission of respiratory viruses like SARS-CoV-2 involves a complex interplay of social,
71 environmental, and biological variables[7]. Numerous observational studies have described risk
72 factors of SARS-CoV-2 transmission across a variety of settings including hospitals[8],
73 households[9], and schools[10,11]. Cumulative evidence suggests that the increased human-to-
74 human transmissibility of SARS-CoV-2 in comparison to SARS-CoV stems from stronger
75 affinity for the primary host receptor angiotensin converting enzyme 2 (ACE2)[12–14]. SARS-
76 CoV-2 binds to ACE2 through its spike glycoprotein, the spike protein undergoes proteolytic
77 cleavage before binding with ACE2 prompting endocytosis and membrane fusion[13]. The
78 Omicron variant of SARS-CoV-2 has a stronger affinity for ACE2 and less reliance on host
79 proteases biasing cell entry towards endocytosis, consequently less cell fusion and syncytia
80 formation occurs[15]. ACE2 is highly expressed in the upper and lower respiratory tract,
81 upregulation may occur in response to stimulation with interferon[16]. SARS-CoV-2 exploits
82 upregulation of *ACE2* in an interferon rich environment (like the early stages of an innate
83 immune response) to spread from cell-to-cell producing a high viral titre[17]. In the later stages
84 of replication, SARS-CoV-2 downregulates *ACE2*, preventing any benefits to the host mediated
85 by interferon stimulated upregulation[18,19]. SARS-CoV-2 has a shifting relationship with
86 ACE2 and like viral load, ACE2 expression fluctuates through the course of viral infection[20–
87 22]. Regardless, SARS-CoV-2 replicates most efficiently in tissues rich with ACE2, the strong
88 positive association between viral load and ACE2 expression at the time of diagnostic testing
89 increase the degree of viral shedding and thereby, the risk of ongoing transmission [23].
90

91 To understand the role of *ACE2* expression in SARS-CoV-2 transmission, we conducted
92 an infection tracing network analysis of positive testers in concurrent, single-site, hospital

93 associated COVID-19 outbreaks in British Columbia during late 2020 and early 2021. The study
94 aims to: (i) describe the outbreaks in context of person, place, and time, (ii) visualize an infection
95 tracing transmission network to infer the number of secondary cases per primary case and (iii)
96 quantify the relationship between the number of potential secondary cases (outcome) and
97 nasopharyngeal transcription of transmembrane ACE2 (exposure) while adjusting for viral RNA
98 load, and interaction by case designation (patient or healthcare worker). We build from previous
99 work which demonstrated no relationship between transmembrane nasopharyngeal ACE2
100 transcription and age, biological sex or *TMPRSS2* transcription in a sample of COVID-19
101 negative persons[23]. This study contributes novel evidence of how nasopharyngeal ACE2
102 transcription may drive SARS-CoV-2 transmission and highlights the potential role of
103 respiratory masks and infection prevention and control measures in limiting the viruses'
104 nosocomial spread.

105

106 **Methods:**

107

108 *Study Design and Participants:*

109 We conducted surveillance for COVID-19 cases in a British Columbian hospital over a
110 series of outbreaks, from declaration of the first facility associated outbreak on 07-11-2020 to the
111 date the last outbreak was declared over on 04-01-2021 (dd-mm-yyyy). Participants included
112 patients and health care workers who tested positive for COVID-19 upon self-reporting or
113 showing indicative symptoms (e.g. fever, fatigue, cough and loss of taste or smell) or through
114 asymptomatic point prevalence testing during the outbreak investigations. Inclusion criteria were
115 applied to select study participants whose diagnostic specimens were tested centrally at the
116 British Columbia Center for Disease Control Public Health Laboratory, underwent SARS-CoV-2
117 whole genome sequencing, and had adequate remaining volume of nucleic acid extract to assay
118 ACE2 transcription. In the case that a participant was tested for COVID-19 more than once, their
119 first diagnostic specimen from the study period was sampled. Participants who met the inclusion
120 criteria (n = 202) were excluded from the study if their specimen collection container was not
121 identifiable (n = 22), whole genome sequencing failed and was not able to classify the viral
122 lineage (n = 63) or ACE2 transcription was unmeasurable (n = 14) (Figure S1). An analytic
123 dataset of n= 103 participants was used for analysis. Demographic variables of age, biological
124 sex, case description (patient or health care worker) and site of infection/ site of transmission
125 (hospital unit) were drawn from public health laboratory data or the outbreak report of the
126 investigating epidemiologist. Outbreaks were defined by the presence of one or more confirmed
127 cases of COVID-19 which were epidemiologically linked within hospital units (Table S3). The
128 laboratory procedures were performed in a laboratory accredited by the College of American
129 Pathologists and BC's Diagnostic Accreditation Program using validated RT-qPCR and whole
130 genome sequencing protocols[24–26].

131

132 *Ethics Statement:*

133 Ethical approval for the study was sought from the University of British Columbia human
134 ethics board (#H20-01110) which was harmonized with the Fraser Health Authority. Written
135 informed consent was not required. All data was de-identified prior to analysis and the results
136 were not linked back to any identifying records. This study was deemed as minimal risk to the
137 participants involved. To ensure privacy the site of the outbreak series will not be disclosed.

138

139

140 *Procedures:*

141 Participant's diagnostic specimens were collected by nasopharyngeal swab and stored in
142 Universal Transport Medium™ (UTM®) (COPAN) and stored at 4°C before RNA extraction.
143 RNA extraction was performed on the MagMAX-96™ platform with the Viral RNA isolation kit
144 (ThermoFisher). Host and viral gene transcription was assayed by quantitative real-time
145 polymerase chain reaction (RT-qPCR) on the Applied Biosystems 7500 Real-Time PCR
146 platform using TaqMan FastVirus 1-step polymerase (ThermoFisher). Reaction volumes were 20
147 µl, with 5 µl of RNA template, 1 µl of 20X primer/probe, 5 µl FastVirus and 9 µl of nuclease free
148 water. Cycling conditions were set to: 50°C for 5min, 95°C for 20s followed by 40 cycles of
149 95°C for 15s and 60°C for 1 min. As previously described, multiplex RT-qPCR reactions were
150 used to detect host (*ACE2*, *GAPDH*, *RNaseP*) and viral (*E* gene) transcription[27]. Participants
151 were diagnosed COVID-19 positive with an *E* gene cycle threshold value < 38 and a *RNaseP*
152 gene cycle threshold value < 40. The *E* gene Ct values were transformed to genome equivalents
153 per millilitre using a standard curve of SARS-CoV-2 synthetic RNA (MN908947.3) (Twist
154 Bioscience)[23]. Relative gene transcription for *ACE2* was calculated in proportion to the
155 control gene *GAPDH* using the $2^{-\Delta\Delta Ct}$ method[28]. SARS-CoV-2 whole genome sequencing was
156 performed on all diagnostic specimens which tested positive for SARS-CoV-2 by RT-qPCR.
157 Viral genomes were amplified using a 1200bp amplicon scheme and sequenced on an Illumina
158 NextSeq instrument[24]. Genome assembly was performed via a modified ARTIC Nextflow
159 pipeline[29]. Quality control did not pass any genomes with < 85% completeness or < 10X depth
160 of coverage. Viral lineages were assigned using the PANGOLIN tool (Version 1.15.1)[30]. All
161 molecular and genomic testing was performed at the BCCDC-PHL.

162

163

164 *Variable Definition:*

165 Demographic variables of interest were drawn from public health laboratory data, or the
166 outbreak reports provided by the investigating epidemiologist. The measures included in the
167 study are age, biological sex, case description, diagnostic specimen collection date (dd-mm-
168 yyyy), SARS-CoV-2 *E* gene cycle-threshold (Ct) value, *ACE2* gene transcription, SARS-CoV-2
169 lineage (PANGO lineage), site of transmission (hospital unit) and site of infection (hospital unit).
170 Age, *E* gene Ct value (transformed to log₁₀ GE/mL[23]) and *ACE2* gene transcription are
171 continuous numeric variables. Biological sex, case description, viral lineage, collection date and
172 site of transmission/infections are categorical variables. We assumed that collection date equals
173 date of symptom onset for this study because once the hospital declared an outbreak, patients and
174 health care workers were required to be tested at the onset of symptoms. *ACE2* gene
175 transcription was transformed to a categorical value using the mean transcription value ($X_{\square} =$
176 0.00, SD = 1.08) of COVID-19 negative testers, from a previous study which collected a random
177 sample of n = 212 nasopharyngeal specimens in British Columbia during 2020[23]. The number
178 of potential secondary cases per primary case was determined by infection tracing transmission
179 network analysis. *ACE2* gene transcription and number of potential secondary cases are the
180 exposure and outcome of interest. Viral load and case description were included in multivariable
181 analysis because, they meet the definition of a confounder and are a common cause of the
182 exposure (*ACE2* gene transcription) and outcome (number of secondary cases)[31]. Viral load
183 and *ACE2* gene transcription share a strong positive association, people with high *ACE2* gene
184 transcription were found to have high viral loads[32]. Viral load relates to transmission in that

185 people with high viral loads may shed more infectious virus[33,34]. Case description (patient or
186 healthcare worker) relates to *ACE2* gene transcription because patients may have comorbidities
187 or receive medications which affect *ACE2* transcription[35]. Health care workers have additional
188 social connections relative to in-patients, as they can leave work and be exposed to SARS-CoV-2
189 outside of clinical areas or in the community[8].

190

191 *Statistical Analysis:*

192

193 Descriptive Statistics:

194 The analytic data (n = 103) was used for bivariate analysis. The variables of interest were
195 stratified by case description and categorical *ACE2* transcription. An epidemiological curve was
196 visualized for the series of concurrent hospital outbreaks from 07-11-2020 to 04-01-2021 (dd-
197 mm-yyyy). Parametric statistical tests were used given the large sample size of our study[36].

198

199 Infection Tracing Network Analysis:

200 A matrix of all possible transmission pairs was permuted using SARS-CoV-2 lineage
201 classifications, for two cases to form a pair they had to share the same lineage. SARS-CoV-2
202 lineages circulating in the hospital were diverse enough that the minimal difference of single
203 nucleotide polymorphisms between them was unlikely to have occurred by mutation during a
204 single transmission event, suggestion multiple independent introductions (Table S4). Four
205 assumptions (i-iv) were used to select potential transmission pairs from all possible
206 permutations. The first assumption (i) stipulated that specimen collection date (symptom onset
207 date) of the primary case was before that of the secondary case. The second assumption (ii)
208 affirms that the primary case's unit of transmission equals the secondary case's unit of infection.
209 The third assumption (ii) holds that the collection date of the secondary case is at least one-serial
210 interval (5 days) from that of the primary case[37]. The fourth assumption (iv) dictates that the
211 collection date of the secondary case is not more than three-serial intervals (15 days) from the
212 primary case[38]. Potential transmission pairs, which met the four-assumptions, were stratified
213 by categorical *ACE2* transcription (High/Low) or viral lineage and plotted overtime.

214

215 Primary Analysis:

216 Multivariable analysis was performed to estimate the relationship between *ACE2*
217 transcription and number of secondary cases using a Poisson generalized linear regression
218 model. Variable importance was assessed conceptually using the common cause criterion and
219 statistically by the partial F-test. Collinearity was measured using the variable inflation factor,
220 variables with a value greater than five were excluded[39]. Effect modification terms were
221 included if they were statistically significant and supported conceptually. The two assumptions
222 of Poisson models; overdispersion and zero inflation were checked using a ratio of residual
223 deviance to degrees of freedom (theta)[40] and the score test[41], respectively. If the specified
224 Poisson model failed to meet either of these assumptions than an alternative quasi-Poisson or
225 Negative Binomial (NB) model was tested, and the assumptions re-examined. Model fit was
226 measured by the Akaike information criterion[42].

227

228

229 Sensitivity Analysis:

230 Sensitivity analysis was performed to measure the impact of assumptions (ii, iii and iv)
231 used to construct the transmission network on the relationship between *ACE2* transcription and
232 number of secondary cases. The assumptions were excluded independently, and the transmission
233 network was iteratively reconstructed with (n-1) assumptions. Additionally, the fourth
234 assumption (iv) was challenged by changing the infectious period from 15 days (three serial
235 intervals) to 10 days (two serial intervals). The number of secondary cases was computed for
236 each transmission network and used in multivariable analysis.

237 Statistical analysis was performed in R version 4.04 using the packages: readxl,
238 tidyverse, dataexplorer, ggpubr, car, ggsci, stringr, tableone, rio, remotes, lubridate, dplyr,
239 epicontacts, AER, devtools, rlang, DHARMA, MASS, pscl, epiR, EpiCurve[43].

240
241

242 **Results:**

243

244 Descriptive Statistics:

245 The analytic dataset contains (n = 103) cases of COVID-19 associated with a single-site
246 concurrent series of hospital outbreaks from 07-11-2020 to 04-01-2021 (dd-mm-yyyy) in British
247 Columbia, Canada. Participant characteristics are displayed in Table 1, where the variables of
248 interest are stratified by case description (Patients or Health Care Workers) (Table 1). The
249 bivariate relationship between variables and categorical *ACE2* transcription was also investigated
250 (Table S1). Most cases occurred in patients n = 57 (55%), while n = 48 infections were observed
251 in health care workers (45%). The mean age of patients associated with the hospital outbreaks
252 was 78.61 years, health care workers were significantly younger with a mean age of 41.11 years
253 (P < 0.001). Most of the healthcare workers (n = 41, 89%) and patients were biologic females (n
254 = 33, 58%). *ACE2* transcription and viral load did not differ between case descriptions (P = 0.86,
255 P = 0.30). Six SARS-CoV-2 lineages were characterized by whole genome sequencing, two of
256 which did not have more than one case (B.1.128 and B.1.36.38). The highest proportion of
257 observed SARS-CoV-2 infections were either SARS-CoV-2 lineage AL.1 (n = 56) or B.1.2 (n =
258 40) (Table 1), these two lineages have at least a five SNP difference between them (Table S4).

259

260 An epidemiological curve was made to show the incidence of positive testers per week
261 over the course of the hospital associate outbreaks. The outbreaks spanned ten epidemiological
262 weeks (Week-#45-2020 to Week-#1-2021) and possesses a non-normal distribution (Figure 1A
263 & B). We are cautious to directly interpret the incidence curve as infection prevention and
264 control practices implemented during the outbreaks (like point prevalence testing and stoppage
265 of admissions) likely biases the observed incidence of SARS-CoV-2 cases overtime. A first peak
266 in cases occurred on Week #46-2020 and a second on Week #52-2020. In the first phase of the
267 outbreaks, many cases occurred on the second floor of the hospital in units 2A, 2B and 2C. Later
268 transmission was predominately observed on floors four or five in units 4B, 4C, 4D and 5A
269 (Figure 1A). Multiple introductions of SARS-CoV-2 into the hospital environment occurred over
270 the surveillance period; however, timely and effective infection prevention and control measures
271 limited transmission of several variants like B.1.36.38, B.1.128 and B.1.279 (Table S3, Figure
272 S2).

273

274 Transmission Network:

275 Permuting all possible transmission pairs in which the primary and secondary case share
276 the same SARS-CoV-2 lineage yielded $n = 9389$ combinations. Applying the first assumption (i)
277 filtered the possible transmission pairs to $n = 2167$. The second assumption (ii) eliminated
278 another $n = 1480$ possible pairs for a total of $n = 687$. The third and fourth assumptions restricted
279 the possible pairs to $n = 382$ and $n = 76$, respectively. A directed transmission network was
280 constructed from $n = 103$ cases with $n = 76$ contacts. The network captures $n = 55$ transmission
281 events for viral lineage AL.1 and $n = 39$ for B.1.2; transmission of the other viral lineages was
282 either too low (only one case reported) or did not meet the assumption criteria (Figure 2B). The
283 nodes of the transmission network are shown stratified by categorical *ACE2* transcription level
284 (Low or High) (Figure 2A). The distribution of *ACE2* transcription among hospital associated
285 cases was tested with a single sample proportion test, 82% of cases had above average *ACE2*
286 transcription (84/103, $P < 0.001$). Transmission pairs were further stratified into primary ($n = 34$)
287 and secondary cases ($n = 28$). Primary cases possessed predominately high *ACE2* transcription
288 (29/34, $P < 0.001$). *ACE2* transcription was similarly enriched in secondary cases (23/28,
289 $P < 0.01$). Overall, 98.6% of transmission events involved at least one case with high *ACE2*
290 transcription (Table S2).

291

292 Primary Analysis:

293 Multivariable NB regression estimated that a one-unit change in *ACE2* transcription
294 decreases the number of secondary cases in health care workers by -0.13 (95%CI: -0.255 to -
295 0.0181) adjusting for RNA viral load and case description (Table 2). Effect modification was
296 observed between *ACE2* transcription and case description; in patients, a one-unit change in
297 *ACE2* increased the number of secondary cases by 0.187 (95% CI: 0.0101 to 0.370). Therefore, a
298 5 unit increase in *ACE2* transcription may lead to approximately one more SARS-CoV-2
299 secondary case per primary patient case. Poisson and quasi-Poisson regression models were
300 constructed using the same variables, neither provided a better fit to the NB option (Table 2).

301

302 Sensitivity Analysis:

303 A sensitivity analysis was performed to measure the impact of assumptions ii, iii and iv
304 on construction of the transmission network and number of secondary cases. The first
305 assumption- that the symptom onset date of the primary case occurs before the secondary case-
306 was not included in the sensitivity analysis, as breaking this assumption would make the
307 secondary case the primary case. Omission of the second assumption (ii), so that the primary
308 case did not share a hospital unit with the secondary case, increased the number of possible
309 transmission pairs to $n = 538$ (Figure S3). The network was not clearly resolved and no
310 significant relationship between *ACE2* transcription and the number of secondary cases was
311 estimated using a Poisson ($B = -0.17$ [95%CI: -0.903 to 0.558], $P = 0.64$) or NB regression model
312 ($B = -0.01$ [95%CI: -0.082 to 0.0613], $P = 0.8$) (Figure 3). Both models had a worse fit than
313 when used in the primary analysis (Poisson_{AIC} = 705 and NB_{AIC} = 691). Leaving out the third
314 assumption (iii), to appreciate that the secondary case could have been infected in less time than
315 the average serial interval, increased the number of possible transmission pairs to $n = 246$ (Figure
316 S4). A significant relationship between *ACE2* transcription and the number of secondary cases
317 was estimated using a Poisson ($B = -0.60$ [95%CI: -1.08 to -0.125], $P = 0.015$) and NB
318 regression model ($B = -0.11$ [95%CI: -0.215 to -0.0189], $P = 0.03$) (Figure 3). However, neither
319 model fit better than when used in the primary analysis (Poisson_{AIC} = 618 and NB_{AIC} = 551). Re-
320 analysis without the fourth assumption that the infectious period of SARS-CoV-2 does not

321 eclipse 15 days increased the possible transmission pairs to $n = 158$ (Figure S5), no significant
322 relationship between *ACE2* transcription and the number of secondary cases was estimated using
323 a Poisson ($B = 0.0143$ [95%CI: -0.284 to 0.313], $P = 0.64$) or NB regression model ($B = 3.90 \times$
324 10^{-3} [95%CI: -0.0849 to 0.0911], $P = 0.8$) (Figure 3). Additionally, assumption four (iv) was
325 challenged by decreasing the infectious period to 9.5 days or ~ 2 serial intervals (Figure S6,
326 transmission pairs $n = 48$). Applying a shorter infectious period provided the following estimates
327 using a Poisson ($B = -0.270$ [95%CI: -0.454 to -0.0852], $P = 0.00$) and NB regression model (B
328 $= -0.160$ [95%CI: -0.324 to -0.0118], $P = 0.09$) (Figure 3). Importantly, the effect modification
329 term was significant in the NB model, and it provided a better fit than when used in the primary
330 analysis (AIC = 269). In patients a one-unit change in *ACE2* transcription increases the number
331 of secondary cases by 0.268 (95% CI: 0.0315 to 0.518, $P = 0.04$), when adjusting for RNA viral
332 load (Figure 3).

333

334 **Discussion:**

335 This study describes case-to-case transmission within a series of hospital associated
336 SARS-CoV-2 outbreaks in British Columbia during late 2020 and early 2021. We used a
337 combination of epidemiological data from outbreak reports, laboratory measurements of *ACE2*,
338 and SARS-CoV-2 lineages derived from whole genome sequencing to recreate the outbreaks
339 using infection tracing transmission network analysis[44]. The transmission network was
340 resolved to provide the possible number of transmission events (secondary cases) per primary
341 case. Bivariate and multivariable analysis was employed to estimate the relationship between
342 nasopharyngeal *ACE2* transcription and the number of potential secondary cases.

343 Bivariate analysis found that nasopharyngeal *ACE2* transcription did not differ between
344 patients and health care workers. However, *ACE2* transcription was enriched in cases, more than
345 fifty percent of the cases had 'High' *ACE2*. The transmission network constructed with all four
346 assumptions provided $n = 76$ transmission events for analysis. The simplest recreation of the
347 outbreaks was provided by a sensitivity analysis where the fourth assumption (iv) was changed
348 to stipulate an infectious period of 9.5 days (~ 2 serial intervals), which yielded $n = 48$
349 transmission events. Multivariable analysis with Poisson regression models was inferior to NB
350 regression as the number of secondary cases was over dispersed. In the primary analysis, NB
351 regression estimated that a one-unit change in nasopharyngeal *ACE2* transcription decreases the
352 number of secondary cases in health care workers by $B = -0.132$ (95%CI: -0.255 to -0.0181, $P =$
353 0.04) and increases transmission in patients by $B = 0.187$ (95% CI: 0.0101 to 0.370, $P = 0.04$).
354 Sensitivity analysis using a shorter infectious period of 9.5 days, provided comparable results, no
355 association was found between nasopharyngeal *ACE2* transcription and SARS-CoV-2
356 transmission from health care workers ($P = 0.09$). In patients, nasopharyngeal *ACE2* expression
357 was associated with secondary transmission $B = 0.27$ (95% CI: 0.0315 to 0.518, $P = 0.04$)
358 adjusting for RNA viral load (Figure 3A & B).

359 Viral transmission exemplifies a complex system where understanding the mechanism of
360 transmission requires deeper analysis than observing the sum of its components. This
361 observational study describes nasopharyngeal *ACE2* transcription as a component of SARS-
362 CoV-2 transmission. In a series of hospital associated outbreaks in British Columbia
363 nasopharyngeal *ACE2* transcription was positively associated with the number of secondary
364 cases (ongoing transmission) in patients but not health care workers. The reason for this
365 difference may stem from health care workers wearing personal protective equipment while
366 providing care. The Public Health Agency of Canada recommends that health care workers

367 providing care to COVID-19 positive patients, as a minimum, adhere to droplet and contact
368 precautions [47][45]. If care requires aerosol generating procedures, then the health care worker
369 dons a N95 respirator with a gown, gloves, and eye protection[45]. Surgical masks and N95
370 respirators provide a physical barrier between the mucosal membrane of the nasopharyngeal
371 passage and virus carrying droplets or particles suspended in the air. The design and intended use
372 of respirators and surgical masks differ. Respirators are designed to prevent inhalation of
373 airborne particles and must fit tightly to the user's face. Surgical masks are designed to protect
374 others from aerosolized droplet production from the wearer's upper respiratory system[46]. In
375 either case, physical barrier provided by a mask can prevent SARS-CoV-2 viral particles from
376 binding to ACE2 proteins on the surface of host cells and initiating the viral replication cycle.
377 Masking may not completely prevent exposure to SARS-CoV-2 yet still decreases the infectious
378 dose below the level necessary for infection[47]. Various studies have demonstrated the utility of
379 surgical masks and N95 respirators at preventing COVID-19 or infection with other respiratory
380 pathogens[47–49]. Use of surgical masks and social distancing was associated with a reduction
381 of 44.9 COVID-19 cases per 1000 students and staff in Boston area school districts. This
382 reduction represents a 4.49% decrease in the incidence of SARS-CoV-2[50]. A clinical trial
383 investigating the use of surgical masks or N95 respirators to prevent SARS-CoV-2 infection in
384 health care workers found no difference in the masks' efficacy to protect from infection[51].
385 This suggests that when worn by health care workers, surgical masks and N95 respirators have
386 comparable efficacy to reduce respiratory infections transmitted by small, aerosolized particles
387 <5 μm . Taken together, this evidence supports the hypothesis that health care workers in our
388 study were sufficiently protected by their personal protective equipment to negate the association
389 between nasopharyngeal *ACE2* transcription and secondary transmission. In contrast,
390 hospitalized patients did not wear PPE while receiving care and nasopharyngeal *ACE2*
391 transcription possessed a positive association with secondary transmission. The principle of a
392 mask protecting the wearer from causing transmission instead of protecting contacts from
393 acquiring infection parallels how high nasopharyngeal *ACE2* transcription in an infected person
394 may produce more secondary cases. High nasopharyngeal *ACE2* transcription may promote
395 viral shedding in the upper airway and thus the production of finer aerosols from talking,
396 singing, or sneezing. Fine aerosols can spread further than the large ones, produced lower in the
397 respiratory tract, and pose an increased risk of infection to contacts[52]. As PPE use was not
398 measured in our study competing hypotheses could explain the apparent difference in the
399 relationship between *ACE2* transcription and transmission among health care workers and
400 patients. An unmeasured confounding variable present for health care workers but not patients
401 could bias the relationship between *ACE2* transcription and secondary transmission. For
402 example, health care workers have variable shift lengths and leave the hospital daily after work;
403 therefore, their contact time with an infected patient differs from that of an inpatient who shares
404 the same hospital unit. This example also serves to demonstrate the complexity of measuring
405 SARS-CoV-2 and other respiratory pathogen's transmission. We acknowledge that SARS-CoV-
406 2 transmission occurs due to an intricate balance of social, biological, and environmental risk-
407 factors of which nasopharyngeal *ACE2* transcription may contribute a singular role[7].

408 Regulators of *ACE2* transcription in the lower respiratory tract are well documented a
409 lesser evidence base exists for the upper respiratory tract. Importantly, upper, and lower airway
410 *ACE2* transcription are not strongly corelated indicating that they may occur independently of
411 each other[53]. In previous work we found that nasopharyngeal transcription of *ACE2* did not
412 differ by age (within adults over the age of eighteen) or biological sex[27], a finding which was

413 further supported by this study. High nasopharyngeal *ACE2* expression has been associated with
414 long term inhaled corticosteroid use and exposure to fine particulate matter $PM_{2.5}$. Below
415 average, low nasopharyngeal *ACE2* transcription is associated with type 2 inflammation
416 mediated by the cytokines IL-4, IL-5, and IL-13[54,55]. Therefore, individuals with asthma or
417 allergic rhinitis may have lower upper airway *ACE2* expression than those that do not. Further
418 studies are required to understand additional predictors of upper airway *ACE2* expression and if
419 it relates to that of the lower airway.

420

421 **Strengths and limitations:**

422 The described study has several limitations in design, data collection and analysis.
423 Sampling cases of SARS-CoV-2 but not their contacts prevented us from constructing a more
424 robust transmission network[44]. Contact tracing data would benefit our analysis by increasing
425 power of the study and allow estimation of the relationship between nasopharyngeal *ACE2*
426 transcription and lack of transmission. Estimating the relationship between nasopharyngeal
427 *ACE2* transcription and secondary transmission in only confirmed cases may have resulted in
428 selection bias, where we selected for *ACE2* measurements in persons that had been exposed and
429 infected by SARS-CoV-2[56]. Sampling from a population of hospitalized patients may also
430 have introduced Berkson's bias (admission rate bias) into the study and restricts our ability to
431 generalize the results to other sub-groups or the community[56]. The hospitalized patients could
432 share an unmeasured exposure, comorbidity or drug treatment which unknowingly affected their
433 nasopharyngeal *ACE2* transcription. Performing a sensitivity analysis helped us understand the
434 importance of our assumptions in building the infection tracing transmission network. The
435 assumption that the primary and secondary case shared the same hospital unit, proved the most
436 important. Without knowing the place of exposure, the transmission network would not have
437 resolved transmission pairs. Whole genome sequencing provided limited specificity of
438 transmission events when the SARS-CoV-2 outbreak was short and genomes were classified by
439 lineage and not at the resolution of single nucleotide polymorphisms (SNPs). Incorporating SNPs
440 into the analysis may increase resolution of the transmission network by more accurately
441 determining transmission pairs. Using RT-qPCR to measure *ACE2* transcription and RNA viral
442 load overapproximates available *ACE2* protein and viral particles[23]. Future work should aim
443 to re-estimate the association between nasopharyngeal *ACE2* transcription and secondary cases
444 using data from a SARS-CoV-2 household transmission study. The design of a household
445 transmission study has the benefits of selecting participants from a non-hospitalized population,
446 observing secondary infections and contacts within family clusters in a context with limited use
447 of personal protective equipment.

448

449 **Conclusion:**

450 We estimate the association between nasopharyngeal *ACE2* transcription and secondary
451 SARS-CoV-2 transmission in a series of hospital associated outbreaks in British Columbia from
452 late 2020 to early 2021. Analysis shows that 98.6% of transmission pairs and 85% of primary
453 cases had high nasopharyngeal *ACE2* transcription. Multivariable analysis adjusting for RNA
454 viral load and interaction by case description found that nasopharyngeal *ACE2* transcription was
455 positively associated with SARS-CoV-2 transmission in hospital patients but not health care
456 workers. We postulate that use of masks among health care workers explains this difference,
457 transmission from health care workers with high *ACE2* was interrupted by barrier protection.
458 SARS-CoV-2 transmission remains a complex and unresolved phenomenon driven by biological,

459 environmental, and social risk factors. Differential nasopharyngeal ACE2 transcription has been
460 observed in COVID-19 negative persons and having high- above average- expression of ACE2
461 may serve as a risk factor for transmission of SARS-CoV-2.

462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481

482 **References:**

- 483
- 484 1. Long, B.; Brady, W.J.; Koyfman, A.; Gottlieb, M. Cardiovascular Complications in
485 COVID-19. *Am J Emerg Med* **2020**, *38*, 1504–1507, doi:10.1016/j.ajem.2020.04.048.
 - 486 2. Dhar, D.; Dey, T.; Samim, M.M.; Padmanabha, H.; Chatterjee, A.; Naznin, P.; Chandra,
487 S.R.; Mallesh, K.; Shah, R.; Siddiqui, S.; et al. Systemic Inflammatory Syndrome in
488 COVID-19–SISCOV Study: Systematic Review and Meta-Analysis. *Pediatr Res* **2022**, *91*,
489 1334–1349, doi:10.1038/s41390-021-01545-z.
 - 490 3. Guo, T.; Fan, Y.; Chen, M.; Wu, X.; Zhang, L.; He, T.; Wang, H.; Wan, J.; Wang, X.; Lu,
491 Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease
492 2019 (COVID-19). *JAMA Cardiol* **2020**, *5*, 811, doi:10.1001/jamacardio.2020.1017.
 - 493 4. CHAN-YEUNG, M.; XU, R.-H. SARS: Epidemiology. *Respirology* **2003**, *8*, S9–S14,
494 doi:10.1046/j.1440-1843.2003.00518.x.
 - 495 5. Zhang, A.-R.; Shi, W.-Q.; Liu, K.; Li, X.-L.; Liu, M.-J.; Zhang, W.-H.; Zhao, G.-P.; Chen,
496 J.-J.; Zhang, X.-A.; Miao, D.; et al. Epidemiology and Evolution of Middle East
497 Respiratory Syndrome Coronavirus, 2012–2020. *Infect Dis Poverty* **2021**, *10*, 66,
498 doi:10.1186/s40249-021-00853-0.
 - 499 6. Singanayagam, A.; Hakki, S.; Dunning, J.; Madon, K.J.; Crone, M.A.; Koycheva, A.;
500 Derqui-Fernandez, N.; Barnett, J.L.; Whitfield, M.G.; Varro, R.; et al. Community
501 Transmission and Viral Load Kinetics of the SARS-CoV-2 Delta (B.1.617.2) Variant in
502 Vaccinated and Unvaccinated Individuals in the UK: A Prospective, Longitudinal, Cohort
503 Study. *Lancet Infect Dis* **2022**, *22*, 183–195, doi:10.1016/S1473-3099(21)00648-4.

- 504 7. Leung, N.H.L. Transmissibility and Transmission of Respiratory Viruses. *Nat Rev*
505 *Microbiol* **2021**, *19*, 528–545, doi:10.1038/s41579-021-00535-6.
- 506 8. Lindsey, B.B.; Villabona-Arenas, Ch.J.; Campbell, F.; Keeley, A.J.; Parker, M.D.; Shah,
507 D.R.; Parsons, H.; Zhang, P.; Kakkar, N.; Gallis, M.; et al. Characterising Within-Hospital
508 SARS-CoV-2 Transmission Events Using Epidemiological and Viral Genomic Data
509 across Two Pandemic Waves. *Nat Commun* **2022**, *13*, 671, doi:10.1038/s41467-022-
510 28291-y.
- 511 9. Madewell, Z.J.; Yang, Y.; Longini, I.M.; Halloran, M.E.; Dean, N.E. Household
512 Transmission of SARS-CoV-2. *JAMA Netw Open* **2020**, *3*, e2031756,
513 doi:10.1001/jamanetworkopen.2020.31756.
- 514 10. Cowger, T.L.; Murray, E.J.; Clarke, J.; Bassett, M.T.; Ojikutu, B.O.; Sánchez, S.M.;
515 Linos, N.; Hall, K.T. Lifting Universal Masking in Schools — Covid-19 Incidence among
516 Students and Staff. *New England Journal of Medicine* **2022**,
517 doi:10.1056/NEJMoa2211029.
- 518 11. Cordery, R.; Reeves, L.; Zhou, J.; Rowan, A.; Watber, P.; Rosadas, C.; Crone, M.; Storch,
519 M.; Freemont, P.; Mosscrop, L.; et al. Transmission of SARS-CoV-2 by Children to
520 Contacts in Schools and Households: A Prospective Cohort and Environmental Sampling
521 Study in London. *Lancet Microbe* **2022**, *3*, e814–e823, doi:10.1016/S2666-
522 5247(22)00124-0.
- 523 12. Li, F.; Li, W.; Farzan, M.; Harrison, S.C. Structure of SARS Coronavirus Spike Receptor-
524 Binding Domain Complexed with Receptor. *Science (1979)* **2005**, *309*, 1864–1868,
525 doi:10.1126/science.1116480.
- 526 13. Mannar, D.; Saville, J.W.; Zhu, X.; Srivastava, S.S.; Berezuk, A.M.; Tuttle, K.S.;
527 Marquez, A.C.; Sekirov, I.; Subramaniam, S. SARS-CoV-2 Omicron Variant: Antibody
528 Evasion and Cryo-EM Structure of Spike Protein–ACE2 Complex. *Science (1979)* **2022**,
529 *375*, 760–764, doi:10.1126/science.abn7760.
- 530 14. Shang, J.; Ye, G.; Shi, K.; Wan, Y.; Luo, C.; Aihara, H.; Geng, Q.; Auerbach, A.; Li, F.
531 Structural Basis of Receptor Recognition by SARS-CoV-2. *Nature* **2020**, *581*, 221–224,
532 doi:10.1038/s41586-020-2179-y.
- 533 15. Meng, B.; Abdullahi, A.; Ferreira, I.A.T.M.; Goonawardane, N.; Saito, A.; Kimura, I.;
534 Yamasoba, D.; Gerber, P.P.; Fatihi, S.; Rathore, S.; et al. Altered TMPRSS2 Usage by
535 SARS-CoV-2 Omicron Impacts Infectivity and Fusogenicity. *Nature* **2022**, *603*, 706–714,
536 doi:10.1038/s41586-022-04474-x.
- 537 16. Ziegler, C.G.K.; Allon, S.J.; Nyquist, S.K.; Mbano, I.M.; Miao, V.N.; Tzouanas, C.N.;
538 Cao, Y.; Yousif, A.S.; Bals, J.; Hauser, B.M.; et al. SARS-CoV-2 Receptor ACE2 Is an
539 Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific
540 Cell Subsets across Tissues. *Cell* **2020**, *181*, 1016–1035.e19,
541 doi:10.1016/j.cell.2020.04.035.
- 542 17. Sui, Y.; Li, J.; Venzon, D.J.; Berzofsky, J.A. SARS-CoV-2 Spike Protein Suppresses
543 ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung
544 Bronchoalveolar Lavage. *Front Immunol* **2021**, *12*, doi:10.3389/fimmu.2021.658428.
- 545 18. Verdecchia, P.; Cavallini, C.; Spanevello, A.; Angeli, F. The Pivotal Link between ACE2
546 Deficiency and SARS-CoV-2 Infection. *Eur J Intern Med* **2020**, *76*, 14–20,
547 doi:10.1016/j.ejim.2020.04.037.

- 548 19. Groß, S.; Jahn, C.; Cushman, S.; Bär, C.; Thum, T. SARS-CoV-2 Receptor ACE2-
549 Dependent Implications on the Cardiovascular System: From Basic Science to Clinical
550 Implications. *J Mol Cell Cardiol* **2020**, *144*, 47–53, doi:10.1016/j.yjmcc.2020.04.031.
- 551 20. Jia, H.P.; Look, D.C.; Shi, L.; Hickey, M.; Pewe, L.; Netland, J.; Farzan, M.; Wohlford-
552 Lenane, C.; Perlman, S.; McCray, P.B. ACE2 Receptor Expression and Severe Acute
553 Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human
554 Airway Epithelia. *J Virol* **2005**, *79*, 14614–14621, doi:10.1128/JVI.79.23.14614-
555 14621.2005.
- 556 21. Ni, W.; Yang, X.; Yang, D.; Bao, J.; Li, R.; Xiao, Y.; Hou, C.; Wang, H.; Liu, J.; Yang,
557 D.; et al. Role of Angiotensin-Converting Enzyme 2 (ACE2) in COVID-19. *Crit Care*
558 **2020**, *24*, 422, doi:10.1186/s13054-020-03120-0.
- 559 22. Ziegler, C.G.K.; Allon, S.J.; Nyquist, S.K.; Mbano, I.M.; Miao, V.N.; Tzouanas, C.N.;
560 Cao, Y.; Yousif, A.S.; Bals, J.; Hauser, B.M.; et al. SARS-CoV-2 Receptor ACE2 Is an
561 Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific
562 Cell Subsets across Tissues. *Cell* **2020**, *181*, 1016-1035.e19,
563 doi:10.1016/j.cell.2020.04.035.
- 564 23. Nikiforuk, A.M.; Kuchinski, K.S.; Twa, D.D.W.; Lukac, C.D.; Sbihi, H.; Basham, C.A.;
565 Steidl, C.; Prystajecy, N.A.; Jassem, A.N.; Krajden, M.; et al. The Contrasting Role of
566 Nasopharyngeal Angiotensin Converting Enzyme 2 (ACE2) Transcription in SARS-CoV-
567 2 Infection: A Cross-Sectional Study of People Tested for COVID-19 in British
568 Columbia, Canada. *EBioMedicine* **2021**, *66*, 103316, doi:10.1016/j.ebiom.2021.103316.
- 569 24. Freed, N.E.; Vlková, M.; Faisal, M.B.; Silander, O.K. Rapid and Inexpensive Whole-
570 Genome Sequencing of SARS-CoV-2 Using 1200 Bp Tiled Amplicons and Oxford
571 Nanopore Rapid Barcoding. *Biol Methods Protoc* **2020**, *5*,
572 doi:10.1093/biomethods/bpaa014.
- 573 25. Messmann, R.; Dietl, A.; Wagner, S.; Domenig, O.; Jungbauer, C.; Luchner, A.; Maier,
574 L.S.; Schopka, S.; Hirt, S.; Schmid, C.; et al. Alterations of the Renin Angiotensin System
575 in Human End-Stage Heart Failure before and after Mechanical Cardiac Unloading by
576 LVAD Support. *Mol Cell Biochem* **2020**, *472*, 79–94, doi:10.1007/s11010-020-03787-7.
- 577 26. LeBlanc, J.J.; Gubbay, J.B.; Li, Y.; Needle, R.; Arneson, S.R.; Marcino, D.; Charest, H.;
578 Desnoyers, G.; Dust, K.; Fattouh, R.; et al. Real-Time PCR-Based SARS-CoV-2
579 Detection in Canadian Laboratories. *Journal of Clinical Virology* **2020**, *128*, 104433,
580 doi:10.1016/j.jcv.2020.104433.
- 581 27. Nikiforuk, A.M.; Kuchinski, K.S.; Twa, D.D.W.; Lukac, C.D.; Sbihi, H.; Basham, C.A.;
582 Steidl, C.; Prystajecy, N.A.; Jassem, A.N.; Krajden, M.; et al. The Contrasting Role of
583 Nasopharyngeal Angiotensin Converting Enzyme 2 (ACE2) Transcription in SARS-CoV-
584 2 Infection: A Cross-Sectional Study of People Tested for COVID-19 in British
585 Columbia, Canada. *EBioMedicine* **2021**, *66*, 103316, doi:10.1016/j.ebiom.2021.103316.
- 586 28. Livak, K.J.; Schmittgen, T.D. Analysis of Relative Gene Expression Data Using Real-
587 Time Quantitative PCR and the $2^{-\Delta\Delta CT}$ Method. *Methods* **2001**, *25*, 402–408,
588 doi:10.1006/meth.2001.1262.
- 589 29. British Columbia Centre for Disease Control Ncov2019-Artic-Nf (accessed on 22
590 November 2022).
- 591 30. O’Toole, Á.; Scher, E.; Underwood, A.; Jackson, B.; Hill, V.; McCrone, J.T.; Colquhoun,
592 R.; Ruis, C.; Abu-Dahab, K.; Taylor, B.; et al. Assignment of Epidemiological Lineages in

- 593 an Emerging Pandemic Using the Pangolin Tool. *Virus Evol* **2021**,
594 doi:10.1093/ve/veab064.
- 595 31. VanderWeele, T.J. Principles of Confounder Selection. *Eur J Epidemiol* **2019**, *34*, 211–
596 219, doi:10.1007/s10654-019-00494-6.
- 597 32. Gutiérrez-Chamorro, L.; Riveira-Muñoz, E.; Barrios, C.; Palau, V.; Nevot, M.; Pedreño-
598 López, S.; Senserrich, J.; Massanella, M.; Clotet, B.; Cabrera, C.; et al. SARS-CoV-2
599 Infection Modulates ACE2 Function and Subsequent Inflammatory Responses in Swabs
600 and Plasma of COVID-19 Patients. *Viruses* **2021**, *13*, 1715, doi:10.3390/v13091715.
- 601 33. Marc, A.; Kerioui, M.; Blanquart, F.; Bertrand, J.; Mitjà, O.; Corbacho-Monné, M.;
602 Marks, M.; Guedj, J. Quantifying the Relationship between SARS-CoV-2 Viral Load and
603 Infectiousness. *Elife* **2021**, *10*, doi:10.7554/eLife.69302.
- 604 34. Carraturo, F.; del Giudice, C.; Morelli, M.; Cerullo, V.; Libralato, G.; Galdiero, E.; Guida,
605 M. Persistence of SARS-CoV-2 in the Environment and COVID-19 Transmission Risk
606 from Environmental Matrices and Surfaces. *Environmental Pollution* **2020**, *265*, 115010,
607 doi:10.1016/j.envpol.2020.115010.
- 608 35. Onweni, C.L.; Zhang, Y.S.; Caulfield, T.; Hopkins, C.E.; Fairweather, D.L.; Freeman,
609 W.D. ACEI/ARB Therapy in COVID-19: The Double-Edged Sword of ACE2 and SARS-
610 CoV-2 Viral Docking. *Crit Care* **2020**, *24*, 475, doi:10.1186/s13054-020-03195-9.
- 611 36. Kwak, S.G.; Kim, J.H. Central Limit Theorem: The Cornerstone of Modern Statistics.
612 *Korean J Anesthesiol* **2017**, *70*, 144, doi:10.4097/kjae.2017.70.2.144.
- 613 37. Alene, M.; Yismaw, L.; Assemie, M.A.; Ketema, D.B.; Gietaneh, W.; Birhan, T.Y. Serial
614 Interval and Incubation Period of COVID-19: A Systematic Review and Meta-Analysis.
615 *BMC Infect Dis* **2021**, *21*, 257, doi:10.1186/s12879-021-05950-x.
- 616 38. Byrne, A.W.; McEvoy, D.; Collins, A.B.; Hunt, K.; Casey, M.; Barber, A.; Butler, F.;
617 Griffin, J.; Lane, E.A.; McAloon, C.; et al. Inferred Duration of Infectious Period of
618 SARS-CoV-2: Rapid Scoping Review and Analysis of Available Evidence for
619 Asymptomatic and Symptomatic COVID-19 Cases. *BMJ Open* **2020**, *10*, e039856,
620 doi:10.1136/bmjopen-2020-039856.
- 621 39. Craney, T.A.; Surlles, J.G. Model-Dependent Variance Inflation Factor Cutoff Values.
622 *Qual Eng* **2002**, *14*, 391–403, doi:10.1081/QEN-120001878.
- 623 40. Cameron, A.C.; Trivedi, P.K. Regression-Based Tests for Overdispersion in the Poisson
624 Model. *J Econom* **1990**, *46*, 347–364, doi:10.1016/0304-4076(90)90014-K.
- 625 41. van den Broek, J. A Score Test for Zero Inflation in a Poisson Distribution. *Biometrics*
626 **1995**, *51*, 738–743.
- 627 42. Portet, S. A Primer on Model Selection Using the Akaike Information Criterion. *Infect Dis*
628 *Model* **2020**, *5*, 111–128, doi:10.1016/j.idm.2019.12.010.
- 629 43. R Core Team R: A Language and Environment for Statistical Computing. 2013.
- 630 44. Keeling, M.J.; Eames, K.T.D. Networks and Epidemic Models. *J R Soc Interface* **2005**, *2*,
631 295–307, doi:10.1098/rsif.2005.0051.
- 632 45. Public Health Agency of Canada Infection Prevention and Control for COVID-19: Interim
633 Guidance for Acute Healthcare Settings.
- 634 46. Vincent, M.; Edwards, P. Disposable Surgical Face Masks for Preventing Surgical Wound
635 Infection in Clean Surgery. *Cochrane Database of Systematic Reviews* **2016**, *2016*,
636 doi:10.1002/14651858.CD002929.pub3.
- 637 47. Leung, N.H.L.; Chu, D.K.W.; Shiu, E.Y.C.; Chan, K.-H.; McDevitt, J.J.; Hau, B.J.P.;
638 Yen, H.-L.; Li, Y.; Ip, D.K.M.; Peiris, J.S.M.; et al. Respiratory Virus Shedding in

- 639 Exhaled Breath and Efficacy of Face Masks. *Nat Med* **2020**, *26*, 676–680,
640 doi:10.1038/s41591-020-0843-2.
- 641 48. Andrejko, K.L.; Pry, J.; Myers, J.F.; Openshaw, J.; Watt, J.; Birkett, N.; DeGuzman, J.L.;
642 Barbaduomo, C.M.; Dong, Z.N.; Fang, A.T.; et al. Predictors of Severe Acute Respiratory
643 Syndrome Coronavirus 2 Infection Following High-Risk Exposure. *Clinical Infectious*
644 *Diseases* **2022**, *75*, e276–e288, doi:10.1093/cid/ciab1040.
- 645 49. Fennelly, K.P. Particle Sizes of Infectious Aerosols: Implications for Infection Control.
646 *Lancet Respir Med* **2020**, *8*, 914–924, doi:10.1016/S2213-2600(20)30323-4.
- 647 50. Cowger, T.L.; Murray, E.J.; Clarke, J.; Bassett, M.T.; Ojikutu, B.O.; Sánchez, S.M.;
648 Linos, N.; Hall, K.T. Lifting Universal Masking in Schools — Covid-19 Incidence among
649 Students and Staff. *New England Journal of Medicine* **2022**, *387*, 1935–1946,
650 doi:10.1056/NEJMoa2211029.
- 651 51. Loeb, M.; Bartholomew, A.; Hashmi, M.; Tarhuni, W.; Hassany, M.; Youngster, I.;
652 Somayaji, R.; Larios, O.; Kim, J.; Missaghi, B.; et al. Medical Masks Versus N95
653 Respirators for Preventing COVID-19 Among Health Care Workers. *Ann Intern Med*
654 **2022**, *175*, 1629–1638, doi:10.7326/M22-1966.
- 655 52. Wang, C.C.; Prather, K.A.; Sznitman, J.; Jimenez, J.L.; Lakdawala, S.S.; Tufekci, Z.;
656 Marr, L.C. Airborne Transmission of Respiratory Viruses. *Science (1979)* **2021**, *373*,
657 doi:10.1126/science.abd9149.
- 658 53. Hou, Y.J.; Okuda, K.; Edwards, C.E.; Martinez, D.R.; Asakura, T.; Dinnon, K.H.; Kato,
659 T.; Lee, R.E.; Yount, B.L.; Mascenik, T.M.; et al. SARS-CoV-2 Reverse Genetics Reveals
660 a Variable Infection Gradient in the Respiratory Tract. *Cell* **2020**, *182*, 429–446.e14,
661 doi:10.1016/j.cell.2020.05.042.
- 662 54. Kimura, H.; Francisco, D.; Conway, M.; Martinez, F.D.; Vercelli, D.; Polverino, F.;
663 Billheimer, D.; Kraft, M. Type 2 Inflammation Modulates ACE2 and TMPRSS2 in
664 Airway Epithelial Cells. *Journal of Allergy and Clinical Immunology* **2020**, *146*, 80–88.e8,
665 doi:10.1016/j.jaci.2020.05.004.
- 666 55. Takabayashi, T.; Yoshida, K.; Imoto, Y.; Schleimer, R.P.; Fujieda, S. Regulation of the
667 Expression of SARS-CoV-2 Receptor Angiotensin-Converting Enzyme 2 in Nasal
668 Mucosa. *Am J Rhinol Allergy* **2022**, *36*, 115–122, doi:10.1177/19458924211027798.
- 669 56. Westreich, D. Berkson’s Bias, Selection Bias, and Missing Data. *Epidemiology* **2012**, *23*,
670 159–164, doi:10.1097/EDE.0b013e31823b6296.

671

672

673 **Ethical Approval:**

674 Ethical approval for the study was sought from the University of British Columbia human
675 ethics board (#H20-01110) which was harmonized with the Fraser Health Authority. Written
676 informed consent was not required. All data was de-identified prior to analysis and the results
677 were not linked back to any identifying records. This study was deemed as minimal risk to the
678 participants involved. To ensure privacy the site of the outbreak series will not be disclosed.

679

680 **Funding:**

681 This work was funded by the Canadian Institutes of Health Research (#434951) and
682 Genome British Columbia (COV-55).

683

684 **Competing Interests:**

685 The authors have no conflicts of interest to declare.

686

687 **Author Contributions:**

688 A.M.N., K.S.K., K.S. and I.S. conceived and designed the study. Epidemiological
689 reporting, data recording and stewardship was performed by K.S. and S.R. Laboratory data
690 reporting and stewardship was performed by N.P. and A.N.J. Laboratory measurements were
691 taken by A.M.N and K.S.K. Data analysis was performed by A.M.N and K.S.K., D.M.P and
692 M.A.I assisted in interpretation of the results. The manuscript was written by A.M.N, all authors
693 helped with editing and provided their approval for publication.

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708 **Table 1:** Characteristics of analytic data stratified by case designation (n = 103).

Variable	Level	Health Care	Patient	P-Value
		Worker		
		n = 46	n = 57	
Age (mean (SD))		41.1 (10.3)	78.6 (12.1)	<0.001
Biological Sex (%)	Female	41.0 (89.1)	33.0 (57.9)	0.001
	Male	5.00 (10.9)	24.0 (42.1)	
ACE2 Transcription (mean (SD))		2.11 (2.88)	2.00 (3.06)	0.861
RNA Viral Load (mean (SD))		6.94 (1.79)	7.33 (1.98)	0.300
Viral Lineage (%)				0.385
	AL.1	28.0 (60.9)	27.0 (47.4)	
	B.1.128	0.00 (0.00)	1.00 (1.80)	

B.1.2	14.0 (30.4)	25 (43.9)
B.1.279	0.00 (0.00)	2.00 (3.50)
B.1.36	2.00 (4.30)	1.00 (1.80)
B.1.36.36	1.00 (2.20)	0.00 (0.00)
B.1.36.38	1.00 (2.20)	0.00 (0.00)

709 Variables included in the study are stratified by case designation health care worker or patient. P-values for
 710 parametric statistical test performed on continuous (t-test) or categorical data (X^2 test) are reported. Viral lineage
 711 calls are from whole genome sequencing data classified using the PANGOLIN tool (Version 1.15.1). Data is also
 712 available stratified by ‘High’ or ‘Low’ nasopharyngeal ACE2 transcription (Table S1).


713
 714
 715
 716
 717
 718
 719
 720
 721
 722
 723
 724

Table 2: Multivariable analysis of the relationship between ACE2 transcription and the number of SARS-CoV-2 secondary cases.

Multivariable Regression Models			
<i>(Secondary Cases ~ ACE2 Transcription + RNA Viral Load + Case Description + ACE2 Transcription : Case Description)</i>			
Beta Coefficients <i>(95% CI)</i>	Poisson	Quasi-Poisson	Negative Binomial (NB)
ACE2 Transcription in HCW	-0.164 <i>(-0.236- [-0.0919])</i>	-0.164 <i>(-0.273-[-0.0528])</i>	-0.132 <i>(-0.255- [-0.0181])</i>
RNA Viral Load	2.73×10^{-3} <i>($5.34 \times 10^{-3} - 0.0976$)</i>	2.73×10^{-3} <i>(-0.141-0.150)</i>	-0.0197 <i>(-0.164- [0.123])</i>
Case (Patient)	-0.808 <i>(-1.20- [-0.421])</i>	-0.808 <i>(-1.43- [-0.235])</i>	-0.782 <i>(-1.42- [-0.162])</i>

ACE2 Transcription in Patients	0.208 (0.0958-0.320)	0.208 (0.0382-0.382)	0.187 (0.01011-0.370)
AIC	394	--	346
Theta	2.44	2.44	0.922
Score Test (P Value)	P < 0.001	--	P = 0.976

725



726


727

728


729 **Figure 1: Incidence curve of several hospital associated SARS-CoV-2 outbreaks in British Columbia by**
 730 **epidemiological week from 07-11-2020 to 04-01-2021 (n = 103 laboratory confirmed cases).** SARS-CoV-2
 731 incidence follows a non-normal distribution where an initial peak caseload was observed in W46-2020 and a second
 732 lesser case surge occurred in W52-2020. **A)** SARS-CoV-2 cases are stratified by hospital floor, early in the
 733 surveillance period transmission occurred mostly on floor number two and later moved to floors four and five. If the
 734 floor where transmission occurred was not determined by the investigating epidemiologist, then it was coded as
 735 'unknown' for our analysis. **B)** SARS-CoV-2 cases are stratified by viral variant, n = 7 unique SARS-CoV-2
 736 variants were identified by whole genome sequencing participants diagnostic specimens. SARS-CoV-2 variants
 737 AL.1 and B.1.2 caused the highest percentage of cases: AL.1, 55/103, 53% and B.1.2, 39/103, 38%.

738

739



740
741 **Figure 2: Infection tracing transmission network analysis of a series of hospital associated SARS-CoV-2**
742 **outbreaks in British Columbia by epidemiological week from 07-11-2020 to 04-01-2021 (n = 103 laboratory**
743 **confirmed cases).** Nodes represent confirmed cases while the edge show the direction of outgoing transmission, link
744 a primary case with at least one secondary case. **A)** Nodes in the transmission network are stratified by ACE2
745 transcription (high or low), 82% of cases (84/103) had above average, high ACE2 transcription ($P < 0.001$). **B)**
746 Nodes in the transmission network are classified by SARS-CoV-2 viral variant. The viral variants AL.1 and B.1.2
747 caused multiple secondary infections thorough the outbreaks, in the first phase (before Dec.15th, 2020) of the study
748 period most cases were AL.1 and later transitioned to B.1.2 in phase two (after Dec.15th, 2020).
749



750
 751 **Figure 3: Forest plot of point estimates from the association between nasopharyngeal *ACE2* transcription of**
 752 **the primary case and the SARS-CoV-2 secondary cases.** Poisson and Negative Binomial (NB) regression models
 753 were used for the primary analysis and sensitivity analysis of the assumptions used to construct the infection tracing
 754 networks. **A)** Beta-coefficients and ninety-five percent confidence intervals for the association between
 755 nasopharyngeal *ACE2* transcription and secondary cases within health care workers, adjusting for viral load. The
 756 best fit NB model shows no association in the primary analysis or sensitivity analysis (ii, iv or v). A significant
 757 association between nasopharyngeal *ACE2* transcription and the number of SARS-CoV-2 secondary cases was
 758 found for healthcare workers in sensitivity analysis iii, where the serial interval of 5.6 days was not used to build the
 759 transmission network. **B)** Beta-coefficients and ninety-five percent confidence intervals for the association between
 760 nasopharyngeal *ACE2* transcription and secondary cases within patients, adjusting for viral load. The best fit NB
 761 model finds a positive association between in the primary analysis, and sensitivity analysis iii, and v. No association
 762 between nasopharyngeal *ACE2* transcription and the number of SARS-CoV-2 secondary cases was found for

763 patients in sensitivity analysis ii and iv, where assumptions of transmission occurring within hospital units and a
764 15.6-day infectious period were excluded from constructing the transmission network, respectively.